TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36660974
Drug: High-intensity multimodal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity multimodal exercise training (HIT-MMEX) - supervised resistance, weight-bearing, balance and mobility training twice weekly for 8 months
Study: 34637848
Drug: Intensive community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive community-based intervention (weekly group activities including physical activity and education)
Study: 36401471
Drug: Xiehuangjiejing (XHJJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiehuangjiejing (XHJJ) granule, 4.5 g administered 3 times daily
Study: 36401471
Drug: Matched placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo, 4.5 g administered 3 times daily
Study: 33960277
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg daily for three months)
Study: 33119423
Drug: lemborexant 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 5 mg/day
Study: 33119423
Drug: lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 10 mg/day
Study: 33119423
Drug: lemborexant (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant (5 mg/day or 10 mg/day)
Study: 33306634
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg effervescent tablets, three tablets per day for two days prior to RNT)
Study: 33706868
Drug: Platelet reactivity-based
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet reactivity-based strategy (daily measurements of platelet reactivity by Multiplate analyzer)
Study: 33706868
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (P2Y12 receptor inhibitor withdrawn 5 to 7 days before CABG)
Study: 34545997
Drug: Cilostazol (CLS)
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol (CLS) 50 mg twice daily plus escitalopram (ESC) 20 mg once daily for six weeks
Study: 34545997
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus escitalopram (ESC) 20 mg once daily for six weeks
Study: 34973597
Drug: Salsalate (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (1500 mg, twice daily for 4 days)
Study: 32133585
Drug: L-tyrosine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (2.0 g)
Study: 34967382
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency therapy
Study: 34589205
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherries (MC) 30 ml twice daily for 28 days
Study: 34589205
Drug: Placebo 30
Normalized name: Ethinyl Estradiol/Norgestrel;Placebo 30 MCG-0.3 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 ml twice daily for 28 days
Study: 32223116
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation plus clopidogrel
Study: 32068870
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (0.75-6 mg, dosing interval 0.75 mg)
Study: 35459947
Drug: Physiological IntraCytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological IntraCytoplasmic Sperm Injection (PICSI)
Study: 32281648
Drug: Higher threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher threshold (e.g., P < .2)
Study: 35731517
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin 100 mg daily
Study: 32590944
Drug: Intracoronary prourokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary prourokinase (10 ml)
Study: 34602290
Drug: Rucaparib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib treatment
Study: 35977778
Drug: Intrathecal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal hydromorphone (100 μg)
Study: 33013880
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TXA
Study: 33013880
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g TXA
Study: 35834738
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care overground therapy
Study: 33817809
Drug: Adjunctive phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive phototherapy protocol ('Perio‐1') with root surface debridement (RSD)
Study: 33817809
Drug: Adjunctive phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive phototherapy protocol ('Perio‐1') with RSD
Study: 33228744
Drug: Active psychological
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active psychological treatments for depression (specific treatments not detailed)
Study: 32481364
Drug: Huangqi Guizhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangqi Guizhi Wuwu decoction mimetic agent
Study: 33236662
Drug: Moderate fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate fixed-dose hydroxyurea (20 mg/kg/day)
Study: 33236662
Drug: Low fixed-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low fixed-dose hydroxyurea (10 mg/kg/day)
Study: 34320708
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 50 mg dexketoprofen
Study: 33438206
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of medications with limited benefit in hospice patients (cancer and non-cancer diagnoses)
Study: 33438206
Drug: Prescribing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing oral anticoagulants in the emergency department
Study: 33438206
Drug: Conducting electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conducting electronic medication reconciliation
Study: 33438206
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of antihypertensive medications
Study: 33199081
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of continuous wave CO2 laser and fractional ablative CO2 laser (Group 1)
Study: 33078725
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam administered by parents
Study: 33078725
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam administered by doctors
Study: 32252049
Drug: Lactofem oral
Normalized name: citronellene lactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactofem oral probiotic capsule (500 mg daily for 2 months)
Study: 35470105
Drug: Cholecalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (50,000 IU weekly for 8 weeks)
Study: 35470105
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (identical for 8 weeks)
Study: 34688374
Drug: Toripalimab monotherapy
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab monotherapy (n=17)
Study: 34335740
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.3 mg/kg bolus after induction, followed by 0.2 mg/kg/hr infusion for up to 24 hours)
Study: 32012051
Drug: Twice-a-day pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day pain reporting
Study: 35352134
Drug: High inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High inflammation group (CRP ≥ 2.0 mg/L)
Study: 35352134
Drug: Low inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low inflammation group (CRP < 2.0 mg/L)
Study: 36195807
Drug: oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral voriconazole (inhibitor)
Study: 36195807
Drug: intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous voriconazole (inhibitor)
Study: 32127545
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration (standard nasal spray)
Study: 32127545
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration (nebulizer)
Study: 32188915
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/day for 7 days
Study: 33434451
Drug: 4 monthly
Normalized name: tobramycin 28 MG inhalation powder 224 Monthly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 monthly videoconference‐tailored coaching sessions with an advanced practice nurse or social worker, participation in patient appointments via videoconference, access to a website designed for DCGs.
Study: 32933498
Drug: Preoperative induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative induction chemotherapy (2 cycles of FLOT: 5‐FU, leucovorin, oxaliplatin, docetaxel) followed by preoperative radiochemotherapy (oxaliplatin weekly, 5‐FU plus concurrent fractioned radiotherapy to a dose of 45 Gy)
Study: 32933498
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy alone (4 cycles of FLOT)
Study: 32933498
Drug: Combined chemotherapy/radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy/radiochemotherapy treatment
Study: 32933498
Drug: Preoperative induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative induction chemotherapy (2 cycles of FLOT) followed by preoperative radiochemotherapy
Study: 32933498
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with FLOT alone
Study: 33528516
Drug: 10-mg/d Vericiguat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg/d Vericiguat
Study: 33528516
Drug: 15-mg/d Vericiguat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg/d Vericiguat
Study: 34341196
Drug: Manual separation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual separation followed by topical antibiotic ointment application for 1 week with local hygiene
Study: 35917993
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) administered prior to initial acquisition of a predictive learning task
Study: 34043103
Drug: Eribulin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin as first- or second-line chemotherapy
Study: 34110839
Drug: TAU-only (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU-only (treatment as usual)
Study: 33667194
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone (T)
Study: 33667194
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor letrozole (Lz)
Study: 33619855
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion of ropivacaine
Study: 33789432
Drug: Dry Needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Needling Combined With Guideline‐Based Physical Therapy
Study: 33789432
Drug: Guideline‐Based Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline‐Based Physical Therapy
Study: 34600589
Drug: IL-6 receptor
Normalized name: Humanised anti-IL-6 receptor monoclonal antibody
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IL-6 receptor antagonists (IL-6RAs)
Study: 34600589
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IL-6RAs and steroids)
Study: 32339359
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n=31)
Study: 33724264
Drug: CRT-D (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D (Cardiac Resynchronization and Defibrillator Therapy)
Study: 33068691
Drug: EX +
Normalized name: Freeflex + Transfer Adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX + 500 mg/day resveratrol (EX500)
Study: 33068691
Drug: EX +
Normalized name: Freeflex + Transfer Adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX + 1000 mg/day resveratrol (EX1000)
Study: 32247660
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg) plus acetaminophen (15 mg/kg)
Study: 33197226
Drug: Continued chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued chemotherapy in exploratory analysis of PD-L1-positive population (n = 137)
Study: 35072758
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg daily) + Sertraline (100 mg daily)
Study: 35072758
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Sertraline (100 mg daily)
Study: 34708642
Drug: Qingre Huatan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Huatan formulae + Western Medicine
Study: 34708642
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western Medicine only
Study: 34988730
Drug: Intradermal tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal tranexamic acid injection combined with low fluence Q-switched Nd:YAG laser
Study: 34988730
Drug: Intradermal tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal tranexamic acid injection alone
Study: 33197270
Drug: 5% ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ibuprofen gel
Study: 33197270
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin cream
Study: 33197270
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of ibuprofen and capsaicin
Study: 32635181
Drug: Vitamin B‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐6 (50 mg pyridoxine/d)
Study: 32635181
Drug: GSH (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSH (500 mg/d)
Study: 35971130
Drug: Everyday Life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everyday Life Rehabilitation (ELR) plus treatment as usual (TAU)
Study: 33551217
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose diet (HiFruD, 1.4 g kg−1 day−1 fructose + 0.1 g kg−1 day−1 glucose)
Study: 33551217
Drug: Low fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low fructose diet (LoFruD, <10 g/d)
Study: 33185824
Drug: Harm Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harm Reduction Treatment for Alcohol (HaRT‐A)
Study: 32184026
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of ready-to-use therapeutic food (RUTF)
Study: 32184026
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of ready-to-use therapeutic food (RUTF)
Study: 35896378
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg once daily for 2 weeks
Study: 35896378
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg once daily for 6 weeks
Study: 33658293
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intramuscular respiratory syncytial virus (RSV) F‐protein vaccine
Study: 32113309
Drug: Acoustic quantification
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [ka] sequences
Study: 32113309
Drug: Acoustic quantification
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [pa] sequences
Study: 32113309
Drug: Acoustic quantification
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [ta] sequences
Study: 33152142
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG treatment
Study: 32470975
Drug: Vitamin B-12
Normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-12 supplementation (50 μg daily orally)
Study: 34469628
Drug: Medicines Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicines Management Optimisation Review (MOR)
Study: 32988598
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D therapy (approximately 1,200 IU daily)
Study: 35857130
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg xanthohumol
Study: 35435296
Drug: Trimax-360 Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimax-360 Serum applied twice a day for 98 days
Study: 32514751
Drug: CBD 10
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 1000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 10 mg/kg/day plus current clinical management (CCM)
Study: 32514751
Drug: CBD 20
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 20 mg/kg/day plus CCM
Study: 32513564
Drug: SC-003 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-003 at 0.3 mg/kg and 0.2 mg/kg
Study: 32513564
Drug: SC-003 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-003 monotherapy or in combination with budigalimab
Study: 36255239
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g CAS+IMD
Study: 36255239
Drug: 8.0 g
Normalized name: PERACETIC ACID 8.0 g in 4000 mL TOPICAL LIQUID [Peraflu D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.0 g CAS+IMD
Study: 36255239
Drug: CAS+IMD combined-dose
Normalized name: CA-170
DrugBank: CA-170 (DB15772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS+IMD combined-dose
Study: 34121357
Drug: Acetaminophen syrup
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen syrup (320 mg/10 ml)
Study: 34121357
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (200 mg/10 ml)
Study: 32079623
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg, 2 weekly for 24 weeks)
Study: 32079623
Drug: Standard fluoropyrimidine‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluoropyrimidine‐based chemotherapy (capecitabine, oxaliplatin for 12 weeks or capecitabine for 24 weeks)
Study: 33626889
Drug: Remote hemodynamic-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote hemodynamic-guided pharmacotherapy (treatment)
Study: 35296293
Drug: Non-surgical spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical spinal decompression therapy (NSD) in addition to routine physical therapy
Study: 35799556
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 mcg)
Study: 32716652
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) + game therapy (GT)
Study: 32716652
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PFMT and PFMT+GT)
Study: 32334045
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation (1.6 mg/day)
Study: 32334045
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MTHFR CC genotype)
Study: 35168622
Drug: Emergency Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Medicine Palliative Care Access (EMPallA) trial
Study: 35377948
Drug: Neoadjuvant durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant durvalumab plus chemotherapy
Study: 33288437
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 μg/24 h) with intermittent micronized progesterone
Study: 35654480
Drug: Alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (10 µg/kg before intubation) + sevoflurane anesthesia
Study: 32729619
Drug: gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gaboxadol 15 mg
Study: 32526195
Drug: Baloxavir (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baloxavir (40 mg for patients <80 kg, 80 mg for patients ≥80 kg)